Precision psychiatry in clinical practice

References

• Agúndez JAG, et al. 2012. Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Front. Genet. 3. doi:10.3389/fgene.2012.00273
   Google Scholar
• Arwood MJ, Chumnumwat S, Cavallari LH, Nutescu EA, Duarte JD. 2016. Implementing pharmacogenomics at your institution: establishment and overcoming implementation challenges. Clin Transl Sci. 9:233–245. doi:10.1111/cts.12404
   PubMed Web of Science ®Google Scholar
• Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, Relling MV, Guchelaar H-J. 2018. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther. 103:599–618. doi:10.1002/cpt.762
   PubMed Web of Science ®Google Scholar
• Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, Feigl AB, Gaziano T, Mowafi M, Pandya A, Prettner K, et al. 2011. The Global Economic Burden of Non-communicable Diseases. Geneva: World Economic Forum.
   Google Scholar
• Border R, Johnson EC, Evans LM, Smolen A, Berley N, Sullivan PF, Keller MC. 2019. No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. Am J Psychiatry. 176:376–387. doi:10.1176/appi.ajp.2018.18070881
   PubMed Web of Science ®Google Scholar
• Borobia AM, Dapia I, Tong HY, Arias P, Muñoz M, Tenorio J, Hernández R, García García I, Gordo G, Ramírez E, et al. 2018. Clinical implementation of pharmacogenetic testing in a hospital of the Spanish National Health System: strategy and experience over 3 years. Clin Transl Sci. 11:189–199. doi:10.1111/cts.12526
   PubMed Web of Science ®Google Scholar
• Bousman CA, Dunlop BW. 2018. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J. 18:613–622. doi:10.1038/s41397-018-0027-3
   PubMed Web of Science ®Google Scholar
• Bousman C, Al Maruf A, Müller DJ. 2019. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry. 32:7–15. doi:10.1097/YCO.0000000000000465
   PubMed Web of Science ®Google Scholar
• Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. 2019. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 20:37–47. doi:10.2217/pgs-2018-0142
   PubMed Web of Science ®Google Scholar
• Bzdok D, Meyer-Lindenberg A. 2018. Machine learning for precision psychiatry: opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging. 3:223–230. doi:10.1016/j.bpsc.2017.11.007
   PubMed Web of Science ®Google Scholar
• Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. 2016. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry. 3:243–250. doi:10.1016/S2215-0366(15)00471-X
   PubMed Web of Science ®Google Scholar
• Corponi F, Fabbri C, Serretti A. 2018. Pharmacogenetics in psychiatry. Adv Pharmacol. 83:297–331. doi:10.1016/bs.apha.2018.03.003
   PubMedGoogle Scholar
• Danielson BSPPB. 2002. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 3:561–597. doi:10.2174/1389200023337054
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2018. Committee for Medicinal Products for Human Use (CHMP) Guideline on good pharmacogenomic practice.
   Google Scholar
• Fabbri C, Serretti A. 2019. Is pharmacogenetics useful in antidepressant treatment? Clin Pharmacol Ther. 106:916–918. doi:10.1002/cpt.1451
   PubMed Web of Science ®Google Scholar
• Fabbri C, Girolamo GD, Serretti A. 2013. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet. 162:487–520. doi:10.1002/ajmg.b.32184
   Web of Science ®Google Scholar
• Fabbri C, Montgomery S, Lewis CM, Serretti A. 2020. Genetics and major depressive disorder. Clin Psychopharmacol Neurosci. 18:1–9. doi:10.9758/cpn.2020.18.1.1
   PubMed Web of Science ®Google Scholar
• Fabbri C, Montgomery S, Lewis CM, Serretti A. 2020. Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. Int Clin Psychopharmacol. doi:10.1097/YIC.0000000000000305
   PubMed Web of Science ®Google Scholar
• Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, et al. 2018. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol. 28:945–954. doi:10.1016/j.euroneuro.2018.05.009
   PubMed Web of Science ®Google Scholar
• Fabbri C, Zohar J, Serretti A. 2018. Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 86:36–44. doi:10.1016/j.pnpbp.2018.05.007
   PubMed Web of Science ®Google Scholar
• Fanelli G, Benedetti F, Kasper S, Kautzky A, Zohar J, Souery D, Montgomery S, Albani D, Ferentinos P, Rujescu D, et al. 2020. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. medRxiv. doi:10.1101/2020.01.15.20017699
   Google Scholar
• FDA. 2020. Pharmacogenetic tests and genetic tests for heritable markers. FDA. [Online]. [accessed 2020 Mar 11]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenetic-tests-and-genetic-tests-heritable-markers
   Google Scholar
• Ferrell PB, McLeod HL. 2008. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 9:1543–1546. doi:10.2217/14622416.9.10.1543
   PubMed Web of Science ®Google Scholar
• Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, et al. 2019. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 111:59–67. doi:10.1016/j.jpsychires.2019.01.003
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, et al; Clinical Pharmacogenetics Implementation Consortium. 2015. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 98:127–134. doi:10.1002/cpt.147
   PubMed Web of Science ®Google Scholar
• Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, et al. 2017. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 102:37–44. doi:10.1002/cpt.597
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement H W, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, et al. 2018. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 51(1-02):9–62. doi:10.1055/s-0043-116492
   PubMed Web of Science ®Google Scholar
• Hong EP, Park JW. 2012. Sample size and statistical power calculation in genetic association studies. Genomics Inform. 10:117–122. doi:10.5808/GI.2012.10.2.117
   PubMedGoogle Scholar
• Iniesta R, Malki K, Maier W, Rietschel M, Mors O, Hauser J, Henigsberg N, Dernovsek MZ, Souery D, Stahl D, et al. 2016. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res. 78:94–102. doi:10.1016/j.jpsychires.2016.03.016
   PubMed Web of Science ®Google Scholar
• Iniesta R, Stahl D, McGuffin P. 2016. Machine learning, statistical learning and the future of biological research in psychiatry. Psychol Med. 46:2455–2465. doi:10.1017/S0033291716001367
   PubMed Web of Science ®Google Scholar
• Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. 2016. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry. 173:174–183. doi:10.1176/appi.ajp.2015.15030331
   PubMed Web of Science ®Google Scholar
• Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. 2013. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics. 14:723–726. doi:10.2217/pgs.13.59
   PubMed Web of Science ®Google Scholar
• Kautzky A, Baldinger P, Souery D, Montgomery S, Mendlewicz J, Zohar J, Serretti A, Lanzenberger R, Kasper S. 2015. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol. 25:441–453. doi:10.1016/j.euroneuro.2015.01.001
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, et al.; CANMAT Depression Work Group. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 61:540–560. doi:10.1177/0706743716659417
   PubMed Web of Science ®Google Scholar
• Lee JA, Lee CR, Reed BN, Plitt DC, Polasek MJ, Howell LA, Cicci JD, Tasca KE, Weck KE, Rossi JS, et al. 2015. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-Risk coronary artery disease patients. Pharmacogenomics. 16:303–313. doi:10.2217/pgs.14.180
   PubMed Web of Science ®Google Scholar
• Lin E, Kuo PH, Liu YL, Yu YWY, Yang AC, Tsai SJ. 2018. A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. Front Psychiatry. 9:290. doi:10.3389/fpsyt.2018.00290
   PubMed Web of Science ®Google Scholar
• Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A. 2015. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 13:69–79. doi:10.1370/afm.1687
   PubMed Web of Science ®Google Scholar
• Maron E, Baldwin DS, Balõtšev R, Fabbri C, Gaur V, Hidalgo-Mazzei D, Hood S, Juhola M, Kampman O, Kasper S, et al. 2019. Manifesto for an international digital mental health network. Digital Psychiatry. doi:10.1080/2575517X.2019.1617575
   Google Scholar
• Mitchell AJ, Selmes T. 2007. Why don’t patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treat. 13:336–346. doi:10.1192/apt.bp.106.003194
   Google Scholar
• Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, et al. 2013. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 33:1156–1164. doi:10.1002/phar.1329
   PubMed Web of Science ®Google Scholar
• O’Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ. 2012. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 92:446–449. doi:10.1038/clpt.2012.117
   PubMed Web of Science ®Google Scholar
• O’Dushlaine C, Ripke S, Ruderfer DM, Hamilton SP, Fava M, Iosifescu DV, Kohane IS, Churchill SE, Castro VM, Clements CC, et al. 2014. Rare copy number variation in treatment-resistant major depressive disorder. Biol Psychiatry. 76:536–541. doi:10.1016/j.biopsych.2013.10.028
   PubMed Web of Science ®Google Scholar
• Patel MJ, Andreescu C, Price JC, Edelman KL, Reynolds CF, Aizenstein HJ. 2015. Machine learning approaches for integrating clinical and imaging features in late-life depression classification and response prediction. Int J Geriatr Psychiatry. 30:1056–1067. doi:10.1002/gps.4262
   PubMed Web of Science ®Google Scholar
• Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F, You R, You E, Tanguay-Sela M, Snook E, et al. 2019. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord. 243:503–515. doi:10.1016/j.jad.2018.09.067
   PubMed Web of Science ®Google Scholar
• PharmGKB. 2020. PharmGKB [Online]. [accessed 2020 Apr 13]. https://www.pharmgkb.org/
   Google Scholar
• Porcelli S, Fabbri C, Spina E, Serretti A, De Ronchi D. 2011. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol. 7:1101–1115. doi:10.1517/17425255.2011.597740
   PubMed Web of Science ®Google Scholar
• Scott SA. 2011. Personalizing medicine with clinical pharmacogenetics. Genet Med. 13:987–995. doi:10.1097/GIM.0b013e318238b38c
   PubMed Web of Science ®Google Scholar
• Serretti A. 2018. The present and future of precision medicine in psychiatry: focus on clinical psychopharmacology of antidepressants. Clin Psychopharmacol Neurosci. 16:1–6. doi:10.9758/cpn.2018.16.1.1
   PubMed Web of Science ®Google Scholar
• Sinyor M, Cheung CP, Abraha HY, Lanctôt KL, Saleem M, Liu CS, Li A, Juda A, Levitt AJ, Cheung AH, et al. 2020. Antidepressant-placebo differences for specific adverse events in major depressive disorder: a systematic review. J Affect Disord. 267:185–190. doi:10.1016/j.jad.2020.02.013
   PubMed Web of Science ®Google Scholar
• Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Bollen J, Demyttenaere K, Kasper S, et al. 2011. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 31:512–516. doi:10.1097/JCP.0b013e3182228619
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. 2015. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 122:5–28. doi:10.1007/s00702-014-1300-5
   PubMed Web of Science ®Google Scholar
• Stratou G, Morency LP. 2017. MultiSense-context-aware nonverbal behavior analysis framework: a psychological distress use case. IEEE Trans Affective Comput. 8:190–203. doi:10.1109/TAFFC.2016.2614300
   Web of Science ®Google Scholar
• Strom CM, Goos D, Crossley B, Zhang K, Buller-Burkle A, Jarvis M, Quan F, Peng M, Sun W. 2012. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med. 14:95–100. doi:10.1038/gim.0b013e3182329870
   PubMed Web of Science ®Google Scholar
• Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, Wendland JR, Lewis CM, McGuffin P, Uher R, et al. 2013. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 73:679–682. doi:10.1016/j.biopsych.2012.10.030
   PubMed Web of Science ®Google Scholar
• Tansey KE, Rucker JJH, Kavanagh DH, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans DM, Hauser J, Henigsberg N, et al. 2014. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics J. 14:395–399. doi:10.1038/tpj.2013.51
   PubMed Web of Science ®Google Scholar
• Taylor D, Barnes TRE, Young AH. 2018. The Maudsley prescribing guidelines in psychiatry. 13th ed. Hoboken, NJ: Wiley.
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al.; STAR*D Study Team. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. AJP. 163:28–40. doi:10.1176/appi.ajp.163.1.28
   Web of Science ®Google Scholar
• Uher R, Tansey KE, Henigsberg N, Wolfgang M, Mors O, Hauser J, Placentino A, Souery D, Farmer A, Aitchison KJ, et al.; GENDEP Investigators. 2013. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. AJP. 170:207–217. doi:10.1176/appi.ajp.2012.12020237
   Google Scholar
• Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ, et al. 2016. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388:P1545–P1602.
   PubMed Web of Science ®Google Scholar
• Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, Staley BJ, Dong H-J, Allan RW, Liu JF, et al. 2014. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet. 166:56–67. doi:10.1002/ajmg.c.31390
   Web of Science ®Google Scholar
• WHO. 2020. Regulatory bodies. [Online]. [accessed 2020 Mar 11]. https://www.who.int/genomics/policy/regulatory_bodies/en/
   Google Scholar
• Zanardi R, Benedetti F, Bella DD, Catalano M, Smeraldi E. 2000. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 20:105–107. doi:10.1097/00004714-200002000-00021
   PubMed Web of Science ®Google Scholar
• Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E. 2001. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 50:323–330. doi:10.1016/S0006-3223(01)01118-0
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ingelman-Sundberg M, Lauschke V. 2017. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 102:688–700. doi:10.1002/cpt.690
   PubMed Web of Science ®Google Scholar